47.53 0.00 (0.00%)
After hours: 4:06PM EST
|Bid||47.10 x 1000|
|Ask||47.88 x 1300|
|Day's Range||45.28 - 47.93|
|52 Week Range||14.01 - 47.93|
|Beta (3Y Monthly)||2.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.64|
The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.
Acadia Pharmaceuticals is the IBD Stock Of The Day as investors look ahead to a presentation of the biotech company's psychosis treatment, a drug known by the test name of pimavanserin.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
ACADIA Pharmaceuticals Inc. , today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related psychosis at the upcoming 12th Clinical Trials on Alzheimer’s Disease Meeting.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
ACADIA Pharmaceuticals Inc. (ACAD) today announced the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s President and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.
Acadia (ACAD) delivered earnings and revenue surprises of 29.27% and 6.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it has initiated the Phase 3 LAVENDER placebo-controlled study to evaluate the efficacy and safety of trofinetide for girls and young women with Rett syndrome. Rett syndrome is a serious and rare neurodevelopmental congenital CNS disorder with symptoms that typically present between six to 18 months of age, and lead to problems with cognitive, sensory, motor, and autonomic function. “There is no approved treatment for Rett syndrome, which is a rare neurological disease that impacts nearly every aspect of a child’s life, resulting in loss of speech, difficulty breathing, lack of motor control, loss of muscle tone and mobility, seizures, and more,” said Jeffrey L. Neul, M.D., Ph.D., Annette Schaffer Eskind Chair and Director, Vanderbilt Kennedy Center; Professor of Pediatrics, Division of Neurology, Pharmacology, and Special Education, Vanderbilt Kennedy Center, Vanderbilt University Medical Center and LAVENDER study investigator.
During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended September 30, 2019 on Wednesday, October 30, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, October 30, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 2264578).
Phase III HARMONY trial conducted by Acadia Pharmaceuticals (ACAD) recently delivered robust statistically superior data (p=0.0033) compared to placebo in time to relapse of dementia-related psychosis (DRP), explains biotech specialist John McCamant, editor of The Medical Technology Stock Letter.
— Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients
ACADIA Pharmaceuticals Inc. today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12th Clinical Trials on Alzheimer’s Disease Meeting, December 4-7, 2019 in San Diego, California.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...